Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.

Authors

Masahiro Torasawa

Masahiro Torasawa

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Masahiro Torasawa , Hidehito Horinouchi , Shogo Nomura , Satoshi Igawa , Maiko Asai , Hidenobu Ishii , Hiroshi Wakui , Ryota Ushio , Tetsuhiko Asao , Yukiko Namba , Ryo Koyama , Isana Katayama , Hironari Matsuda , Shinichi Sasaki , Kazuhisa Takahashi , Yukio Hosomi , Katsuhiko Naoki , Yuichiro Ohe

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8576)

DOI

10.1200/JCO.2023.41.16_suppl.8576

Abstract #

8576

Poster Bd #

203

Abstract Disclosures

Similar Posters

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

First Author: Laurent Mhanna

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.

Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.

First Author: Cody Eslinger